News Channels

06 Jul 2021 Almirall and MC2 Therapeutics announce completion of decentralized procedure in Europe for the topical treatment of mild to moderate psoriasis vulgaris in adults
06 Jul 2021 HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL 295 in Patients with Advanced Solid Tumors in China
06 Jul 2021 Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration
06 Jul 2021 First Patient Dosed with Gadeta's gamma delta TCR Cell Therapy
04 Jul 2021 Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease
04 Jul 2021 ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer
04 Jul 2021 Transcenta Provides Program Update for Anti-Claudin18.2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer
04 Jul 2021 Rallybio Announces Clinical Proof of Concept for RLYB211, an Anti-HPA-1a Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
03 Jul 2021 GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases
02 Jul 2021 Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
02 Jul 2021 Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens
02 Jul 2021 Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM
02 Jul 2021 Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response
02 Jul 2021 Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
02 Jul 2021 HDT Bio Receives Notice to Proceed from FDA for U.S. Phase 1 Clinical Trial of RNA COVID-19 Vaccine
02 Jul 2021 LG Chem Announces Topline Results of LC350189 From the Phase 2 Study (CLUE Study) Promising to Be a New Treatment Alternative With Improved Efficacy and Safety Profiles for Chronic Gout Patients
02 Jul 2021 Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206
02 Jul 2021 Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
02 Jul 2021 Ildong Pharmaceutical starts Phase 1 study of new diabetes therapy in Germany
02 Jul 2021 Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up